Soft Tissue Sarcoma Market

Market Overview:

The 7 major soft tissue sarcoma markets reached a value of US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.7 Billion by 2034, exhibiting a growth rate (CAGR) of 5.31% during 2024-2034.

The soft tissue sarcoma market has been comprehensively analyzed in IMARC's new report titled "Soft Tissue Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Soft tissue sarcoma refers to an uncommon form of cancer that develops in the tissues that surround, connect, and support other body structures. This includes the muscle, fat, blood vessels, nerves, ligaments, and the lining of the joints. The tumors can occur anywhere in the body, although they most commonly form in the limbs, legs, chest, or abdomen. An initial symptom associated with the ailment is a painless lump or swelling in soft tissue. As the tumor increases in size, individuals suffering from this condition may experience other indications, such as pain or soreness. In rare cases, soft tissue sarcomas may cause numbness or tingling if they press on nerves. The diagnosis of the disease is based on a review of the patient's symptoms, medical history, and physical exam. The healthcare provider may also perform various imaging studies, including ultrasound, computed tomography scan, MRI, etc. A needle aspiration biopsy is further required to confirm a diagnosis among patients. In some cases, additional procedures, such as blood tests and a PET scan, may be ordered to check for the spread of cancer to other parts of the body.

The rising prevalence of inherited syndromes, resulting in DNA variations that influence the genes controlling cell proliferation, is primarily driving the soft tissue sarcoma market. In addition to this, the increasing cases of chemical exposure, such as from herbicides, arsenic, dioxin, etc., which can lead to tissue destruction, are also propelling the market growth. Furthermore, the escalating utilization of antineoplastic vascular endothelial growth factor (VEGF) for treating the ailment is creating a positive outlook for the market. This therapy can stop the growth and development of tumors by prohibiting angiogenesis through the inhibition of the VEGF pathway. Additionally, the inflating usage of laparoscopic or robotic surgery owing to its numerous benefits, including a shorter hospital stay, minimal complications, less scarring, etc., is also bolstering the market growth. Moreover, several stakeholders are making extensive investments in R&D activities to introduce effective targeted therapy as a novel treatment alternative for conventional procedures. This, in turn, is acting as another significant growth-inducing factor. In line with this, the emerging popularity of radiation therapies, such as brachytherapy, since they have a lower risk of complications than surgery and can treat tumors in hard-to-reach areas, is expected to drive the soft tissue sarcoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the soft tissue sarcoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for soft tissue sarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the soft tissue sarcoma market in any manner.

Recent Developments:

• In February 2024, QBiotics Group Limited (QBiotics) declared that the US FDA had granted tigilanol tiglate, its lead intratumoral oncology asset, Orphan Drug Designation for the treatment of soft tissue sarcoma. Tigilanol tiglate is a new small-molecule medication discovered and developed by QBiotics as an intratumoral therapy for solid tumors.
• In February 2024, Philogen S.p.A. confirmed that the Phase III FIBROSARC study (NCT04650984) will proceed as per the protocol. FIBROSARC is a Phase III 1:1 randomized experiment comparing L19TNF in conjunction with doxorubicin (Experimental Arm) to doxorubicin alone (Control Arm) in 118 individuals with advanced or metastatic soft tissue sarcoma.
• In November 2023, Intensity Therapeutics demonstrated positive INT230-6 results in patients with refractory soft tissue sarcoma. In the study, INT230-6 increased survival in refractory soft tissue sarcoma patients by nearly 15 months when compared to a synthetic control group.
• In June 2023, Monopar Therapeutics Inc. announced an update on its presently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma.

Key Highlights:

• Soft tissue sarcoma accounts for around 1% and 7-15% of adult and pediatric cancers, respectively.
• Every year, around 8,000 new soft tissue sarcoma cases are diagnosed in the United States, resulting in a higher fatality rate.
• Around 3500 - 4000 men and women die with soft tissue sarcoma in the United States each year.
• Several population-based studies on soft tissue sarcoma have reported rates of 1.8 to 5.0 cases per 100,000 persons per year.
• Young adults have the lowest incidence of soft tissue sarcomas, but it slowly increases until the age of 50.

Drugs:

YONDELIS (trabectedin) is a new, multimodal, synthetic anticancer drug developed from the sea squirt Ecteinascidia turbinata. The anticancer drug prevents tumor cells from growing.

Aldoxorubicin is being developed to treat solid tumors, including advanced soft tissue sarcoma. The medication candidate is delivered via intravenous infusion. The therapeutic candidate specifically targets DNA synthesis. Aldoxorubicin is a doxorubicin conjugation that specifically targets tumors. The drug candidate is a (6-Maleimidocaproyl) doxorubicin hydrazone. It is based on conjugated tumor targeting technology.

L19TNF is a biopharmaceutical product studied for the treatment of advanced soft tissue sarcoma. It is made up of the L19 antibody genetically linked with the Tumor Necrosis Factor (TNF). L19 exclusively binds to the Extra Domain B of Fibronectin, a protein found in malignancies but not in healthy adult tissues. The L19 antibody preferentially localizes TNF, a pro-inflammatory cytokine with anti-tumor action, to neoplastic masses. L19TNF is delivered as a two-hour intravenous infusion.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the soft tissue sarcoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the soft tissue sarcoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current soft tissue sarcoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the soft tissue sarcoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the soft tissue sarcoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the soft tissue sarcoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of soft tissue sarcoma across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of soft tissue sarcoma by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of soft tissue sarcoma by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of soft tissue sarcoma by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with soft tissue sarcoma across the seven major markets?
• What is the size of the soft tissue sarcoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of soft tissue sarcoma?
• What will be the growth rate of patients across the seven major markets?
   

Soft Tissue Sarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for soft tissue sarcoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the soft tissue sarcoma market?
• What are the key regulatory events related to the soft tissue sarcoma market?
• What is the structure of clinical trial landscape by status related to the soft tissue sarcoma market?
• What is the structure of clinical trial landscape by phase related to the soft tissue sarcoma market?
• What is the structure of clinical trial landscape by route of administration related to the soft tissue sarcoma market?